Cargando…
Epigenetic regulation in overcoming chemoresistance /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London :
Academic Press,
2021.
|
| Colección: | Cancer sensitizing agents for chemotherapy ;
15 |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Intro
- Epigenetic Regulation in Overcoming Chemoresistance
- Copyright
- Cover Image Insert
- Aims and Scope for Series ``Cancer Sensitizing Agents for Chemotherapy��
- About the Series Editor
- Aims and Scope of the Volume
- About the Volume Editors
- Preface
- Contents
- Contributors
- Chapter 1: The role of epigenetic regulation in cancer
- Introduction
- DNA methylation
- Histone modification
- RNA regulation
- Conclusion
- References
- Chapter 2: DNA methyltransferase inhibitors (DNMTis) as sensitizing agents to overcome chemoresistance
- Aberrant DNA methylation in cancer
- Deregulation of DNA methyltransferases in cancer
- DNA methyltransferase inhibitors (DNMTis) in cancer therapy
- DNMTi as sensitizing agents for chemotherapy
- Global aberrant DNA methylation induces chemoresistance
- Regional DNA hypermethylation induces chemoresistance
- Antiapoptosis proteins and proliferation-related genes
- DNA damage repair proteins
- Drug-target interactions
- PI3K/Akt pathway
- MicroRNAS
- Combination of DNMTis with other therapies
- Conclusions and prospects
- Acknowledgments
- References
- Chapter 3: Histone deacetylase inhibitors (HDACi), the ongoing epigenetic agents to enhance chemotherapy sensitization
- Introduction
- Classification and application of HDACi
- Hydroxamic acids as HDACi
- Cyclic peptides as HDACi
- Short-chain fatty acids as HDACi
- Benzamides as HDACi
- Other HDACi
- HDACi enhance chemotherapy sensitization
- HDACi enhance sensitization in nonsmall cell lung cancer
- HDACi enhances sensitization in breast cancer
- HDACi enhance sensitization in prostate cancer
- HDACi enhance sensitization in gastric cancer
- HDACi enhance sensitization in liver cancer
- HDACi enhance sensitization in multiple myeloma cells
- Summary
- References.
- Chapter 4: Histone lysine demethylase inhibitor (HDMi) as chemo-sensitizing agent
- The nature of histone modifications
- The dynamics of histone methylation
- Histone lysine demethylases
- Dysregulation of KDMs in cancers
- Aberrant KDMs and chemoresistance
- KDM1/LSD inhibitors as chemo-sensitizing agents
- JmjC demethylase inhibitors as chemo-sensitizing agents
- Concluding remarks
- Acknowledgment
- References
- Chapter 5: Targeting histone lysine methyltransferases for drug sensitization
- An overview of histone methylation
- Histone lysine methyltransferases
- Dysregulation of KMTs in cancers
- Targeting EZH2 for drug sensitization
- G9a, DOT1L, and other KMTs in drug sensitization
- Conclusion and outlook
- Acknowledgments
- References
- Chapter 6: Ribonucleotide base-modifying enzymes and diseases
- Introduction
- Guanine-modification enzymes
- METTL1
- MRM3
- TRMT10A
- TRMT10C
- Cytosine-modification enzymes
- DNMT2
- NAT10
- Uridine-modification enzymes
- ALKBH8
- PUS1
- Adenine-modification enzymes
- TRMT61B
- METTL3
- FTO
- ALKBH5
- Conclusion
- Acknowledgments
- References
- Chapter 7: The combination strategy with epigenetic therapy, chemotherapy, and immunotherapy
- Introduction
- Epigenetic therapy combining with chemotherapy
- Combination of HDAC inhibitors and chemotherapy
- Combination of BET inhibitors and chemotherapy
- Combination of EZH2 inhibitors and chemotherapy
- Combination of LSD1 inhibitors and chemotherapy
- Combination of DNMT inhibitors and chemotherapy
- Epigenetic therapy combining with immunotherapy
- Combination of HDAC inhibitors and immunotherapy
- Combination of BET inhibitors and immunotherapy
- Combination of EZH2 inhibitors and immunotherapy
- Combination of LSD1 inhibitors and immunotherapy
- Conclusion and prospect
- References.
- Chapter 8: Future epigenetic treatment strategies
- Introduction
- The promising epigenetic therapy
- New approaches for epigenetic therapy
- The therapies targeting ncRNA
- miRNA in chemoresistance
- Epigenetic therapies targeting miRNA
- Nanostructured carriers
- Bioactive compounds and Chinese herbal compounds
- The lncRNA in chemoresistance
- Epigenetic therapies targeting lncRNA
- Nanostructured carriers
- Bioactive compounds and Chinese herbal compounds
- The predictive biomarkers
- The dawn and shortage of predictive biomarkers
- The discovering of epigenetic biomarkers
- Combination with targeted therapy
- EGFR-TKIs
- Antiangiogenic agents
- PI3K/AKT/mTOR pathway inhibitors
- Conclusion
- References
- Index.